Immunosuppression for Drug-Induced Interstitial Nephritis


Gearhoid McMahon

Study Acronym:


Acute interstitial nephritis causes acute kidney injury. Treatment varies from nephrologist to nephrologist because one group reads the literature and decides that steroids are best. Others read the same literature and say there is no conclusive evidence for steroids. Others read the literature and throw their hands in the air in frustration.

This study is for all three of those groups. All patients with AKI due to suspected AIN will undergo a renal biopsy in the absence of specific contraindications. Given the fact that the clinical criteria for AIN are not well defined currently, this would mean that many patients who did not have AIN could potentially have biopsies. This can be justified because currently, the definition of AIN is generally clinical and it would provide valuable information about the accuracy of clinical AIN diagnosis while simultaneously providing clinical correlates of AIN for better diagnosis in the future.

Patients with biopsy-proven AIN would be randomized 1:1 to steroid (1mg/kg prednisone to a maximum of 60mg daily) for 2 weeks followed by a taper over 2 months or placebo.

The primary outcome of this study would be dialysis dependence at 3 months.